A novel, rapid and noninvasive test (ODK0501) to detect Streptococcus pneumoniae antigen was evaluated in a Japanese multicenter study. ODK0501 uses polyclonal antibodies to detect C-polysaccharide of S. pneumoniae from sputum by an 21.1% (4/19), respectively. Binax NOW was less capable of detecting S. pneumoniae antigen among patients with underlying COPD. In conclusion, ODK0501 is non-invasive, rapid and accurate tool for diagnosing respiratory infection caused by S.
Bacterial culture and identification, real-time PCR, and ODK0501 assays were performed on sputum samples, and Binax NOW Streptococcus pneumoniae antigen test was performed in urine samples obtained from the same patients. The performance of all tests was compared based on the results of bacterial culture and identification. The sensitivity and specificity of ODK0501 were 89.1% (49/55) and 95.3% (101/106), respectively. We then compared the Binax NOW Streptococcus pneumoniae antigen test with ODK0501 in samples from 142 patients. The sensitivity of ODK0501 and the Binax NOW S. pneumoniae antigen test was 90.0% (45/50) and 62.0% (31/50), respectively (P = 0.002). The relative quantity of S. pneumoniae in expectorated sputum was calculated using real-time PCR and indicated that the possibility of false-positive results of ODK0501 due to indigenous S. pneumoniae was low. The positive and negative concordance rates of ODK0501 and Binax NOW were 96.8% (30/31) and 5 
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.1% (4/19), respectively. Binax NOW was less capable of detecting S. pneumoniae antigen among patients with underlying COPD. In conclusion, ODK0501 is non-invasive, rapid and accurate tool for diagnosing respiratory infection caused by S.
pneumoniae.
INTRODUCTION
Streptococcus pneumoniae is a frequent cause of community-acquired bacterial pneumonia and lower respiratory tract infection (10, 11, 19, 21) , and a major cause of significant morbidity and mortality in Japan and the rest of the world (5).
Since pneumococcal infections are common and can be severe, appropriate initial selection of antimicrobial agents is crucial to an optimal outcome. Rapid and precise identification of the causative agents of infectious diseases is critical but challenging.
Pathogen-oriented, prompt selection and application of antimicrobial agents improves prognosis, reduces medical costs and prevents the development of drug-resistant bacteria due to their inappropriate use. The gold standard, bacterial culture to identify causative microorganisms requires several days to yield result, and is thus unhelpful to the initial selection of appropriate antibacterial drugs. Although Gleckman et al. reported that classic Gram staining of sputum, which is simple and inexpensive, is useful in the diagnosis of bacterial infections (7), Reed and others found that it is ineffective for rapid diagnoses (6, 18). In addition, staining results rely on several factors such as the quality of the sputum samples and the skill of laboratory personnel in processing samples (7) . Thus, Gram staining is not recommended for all patients with community-acquired pneumonia according to the most recent "Infectious Diseases
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Society of America/American Thoracic Society (IDSA/ATS) Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults" (12) .
Urinary antigen detection is an alternative rapid diagnostic technique for detecting antigens of S. pneumoniae and Legionella pneumophila as respiratory pathogens. The Binax NOW Streptococcus pneumoniae urinary antigen test (Binax NOW; Binax, Inc., Portland, ME) detects cell wall antigens secreted in urine using an immunochromatographic method to separate capsular polysaccharides (C-ps) of S.
pneumoniae. The test is noninvasive, rapid (the entire assay can be completed in about 15 minutes) and the specificity and sensitivity of detecting pneumococcal infections in adult patients is > 90% and 50% to 80%, respectively, which allows early diagnosis (3, 8, 16) . Moreover, even when S. pneumoniae cannot be identified by bacterial culture tests after starting antibiotic therapy, the assay can still detect this organism. However, Binax NOW has significant problems including false-positive results due to indigenous S. pneumoniae in children (17) and antigens can be detected even one to three months after treatment (13, 14) .
The ODK0501 (Otsuka Pharmaceutical Co., Ltd. Tokyo, Japan) is a diagnostic kit that uses polyclonal antibodies to detect anti-pneumococcal C-ps, a cell wall antigen of S.
pneumoniae (4) . This immunochromatographic method is rapid, noninvasive and 8 analyzes sputum derived directly from a local infection site. Here, we evaluated the ability ODK0501 to detect S. pneumoniae among patients with lower respiratory tract infection at several Japanese medical institutions and compared its performance with that of Binax NOW. The goal of this study is to prove the usefulness of ODK0501 and to its performance in clinical settings. All adult inpatients or outpatients (age,  15 years) with signs of lower respiratory infections including pneumonia and who had undergone sputum exploration were eligible for inclusion in this study. Prior antibiotics use was not a criterion for exclusion.
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MATERIALS AND METHODS
Study settings
Patients with a provisional diagnosis of lower respiratory infections were assessed by each study investigator to confirm the diagnosis. Clinical information such as existing underlying diseases, prior antibiotics use, number of days from onset until the day when 10 assays were performed, white blood cell (WBC) counts and C-reactive protein (CRP) levels were recorded when the patients registered and retrospectively analyzed.
Sample collection and microbiological investigations
Single expectorated sputum and urine samples were collected from patients who had provided written, informed consent to participate in this study either at a hospital visit or at the time of a presumptive diagnosis of lower respiratory infection. All expectorated sputum samples were conventionally Gram stained and transferred to the microbiology laboratory at Hokusho Central Hospital for expert evaluation. Sputum samples were also cultured at 37°C for 24 hours on blood and chocolate agar at each institution.
Presumptive colonies of bacteria were picked up and identified by biochemical testing.
Some portions of the expectorated sputum samples were placed in different containers at the time of sampling, and stored at -20°C until assay with real-time PCR to detect and quantify S. pneumoniae.
Samples were immediately evaluated using ODK0501 and Binax NOW, otherwise, stored at 4°C until next available day to perform these tests (all assays were performed within 48 hours after collection of samples).
Soluble Legionella pneumophila serogroup 1 antigen in urine was investigated using another immunochromatographic assay and antibodies against Mycoplasma pneumoniae, Chlamydophila psittaci and C. pneumoniae were examined using complement fixation tests.
Measurement and interpretation of results obtained with ODK0501 and Binax
NOW
Each of the participating institutions followed the procedures indicated below.
Sputum samples collected on swabs from containers were shaken in tubes containing sample extract and left for 5 minutes. Swab tips were removed from the tubes while squeezing, a filter was placed on the tube, and the extract was dropped onto the ODK0501 instrument. Approximately 20 minutes later, a positive test result was indicated by the presence of one red test line and one control lines (two lines), whereas a negative result was indicated by the appearance of only the control line.
Results obtained using Binax NOW were measured and interpreted at the each of institutions in accordance with the instructions provided by the manufacturer (3).
Criteria for etiological diagnosis
We evaluated only qualified samples defined according to standard criteria (presence (Table 1) . Real-time PCR proceeded on an ABI7700 or ABI7900 (Applied Biosystems, Foster City, CA) at Kitazato-Otsuka Biomedical Assay Laboratory, Kanagawa, Japan and sequences were analyzed using Sequence Detector V. 
Statistical analysis
The sensitivity and specificity based on the results of the sputum cultures of ODK0501
and Binax NOW was compared using Fisher's exact probability test (two-tailed, level of significant difference P < 0.05). Characteristics of patients with pneumococcal infection diagnosed by both culture and ODK0501 as positive were also compared with Binax NOW-positive or -negative arms. We compared the proportions of qualitative variables using Fisher's exact test, and applied the Mann-Whitney-U test for quantitative variables.
Relationships between the results obtained from real-time PCR for relative amounts of S. pneumoniae among the ODK0501 tested population were also assessed using the Mann-Whitney-U test.
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RESULTS
Composition of patients and etiological agents identified from patients with lower respiratory tract infection
Of the 246 patients exhibiting signs and symptoms compatible with lower respiratory infection, 85 were excluded due to poor sputum quality (presence of either or both of < 25 WBC and > 25 squamous cells per low-power magnification field [× 100]).
We thus investigated samples from 161 inpatients and outpatients (109 males: age range, 22 to 92 y; median age, 71.0 y, 52 females: age range, 15 to 96 y; median age, 65.5 y) with lower respiratory tract infection. Table 2 shows the clinical status of the patients.
Most had pneumonia (79.5%), followed by acute exacerbation of chronic obstructive pulmonary disease (AECOPD) (7.5%), acute bronchitis (6.2%), bronchiectasis (5.0%), chronic bronchitis (1.2%) and only one had a lung abscess. We examined samples from 161 and 142 patients using ODK0501 and Binax NOW, respectively. Table 2 
Overall sensitivity and specificity of ODK0501
The ODK0501 results were positive in 54 of 161 patients (33.5%). Table 2 Comparison of sensitivity and specificity between ODK0501 and Binax NOW 16 We compared the sensitivity and specificity between ODK0501 and Binax NOW against sputum culture results from 142 of the 161 patients (Binax NOW was not performed in 19 of 161 patients).
The ODK0501 test sensitivity was 90.0% (45/50), the specificity was 95.7% (88/92) and the positive and negative predictive values were 91.8% and 94.6%, respectively, based on the sputum cultures. The Binax NOW test sensitivity was 62.0% (31/50), the specificity was 96.7% (89/92) and the positive and negative predictive values were 91.2% and 82.4%, respectively, based on the sputum cultures. Specificity did not significantly differ between the two tests, but the sensitivity of ODK0501 for detecting S. pneumoniae was significantly higher (P = 0.002).
Quantification of Psp A gene in sputum by real-time PCR
We applied real-time PCR to detect and quantify the relative amount of S. pneumoniae in expectorated sputum samples from 161 patients with lower respiratory tract infection. Table 4 summarizes the clinical and laboratory data from 6 patients with lower respiratory infection who generated false-negative results on ODK0501 but were positive in S. pneumoniae cultures. All of these patients had pneumonia and Binax NOW was positive in only one of them (Patient 3). All of these patients had > 1 × 10 5 copies of the Psp A gene.
Comparison between ODK0501 and Binax NOW among patients with pneumococcal infections
We compared the performance of ODK0501 and Binax NOW among 50 patients with pneumococcal infection. Five of 55 pneumococcal patients were excluded due to the 18 absence of Binax NOW data. The positive and negative concordance rates of ODK0501 and Binax NOW were 96.8% (30/31) and 21.1% (4/19), respectively.
Fifteen patients were ODK0501 positive and Binax NOW negative. Table 5 summarizes their clinical and laboratory findings of ODK0501-positive population (Table 4) .
DISCUSSION
Although early diagnosis and antimicrobial drug administration comprise the basic principles of treating pneumococcal as well as other infections, the causative agents may not be correctly identified in many patients at the start of therapy.
Binax NOW is commercially available and widely used in clinical settings, but it possess some disadvantages including false-positive results due to indigenous S. pneumoniae (17) , lasting positivity even 1 -3 months after treatment (13, 14) and no indication for anuric patients. Furthermore, the test has a variable and relatively low sensitivity of 50 to 80% (3, 8, 16) . The novel ODK0501 tests sputum samples derived directly from inflammatory sites using polyclonal antibodies to detect anti-pneumococcal C-ps (20), a common cell wall antigen of S. pneumoniae (4) . Thus, all types of S. pneumoniae can be detected regardless of capsule serotype.
The present clinical study evaluated the applicability of ODK0501 and compared with Binax NOW in adult patients (age,  15 years). The most frequent isolate in the present study was S. pneumoniae (34.7%) followed by H. influenza among 161 patients with lower respiratory tract infection. These findings indicated that the frequency of major isolated bacteria from patients with lower respiratory tract infection was similar to those of other studies, and thus our patient population was valid for analysis.
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ODK0501 yielded favorable results including sensitivity and specificity of 89.1% and 95.3%, respectively, based on sputum culture results from 161 patients. Even when analyzed a total of 120 cases with more superior quality of expectorated sputum (presence of both of > 25 WBC and < 10 squamous cells per low-power magnification field [× 100]) (data not shown), the result showed that higher sensitivity (92.9 %) and almost equal specificity (93.6 %). The sensitivity (87.2%) and specificity (95.1%) was also favorable when evaluated among 128 pneumonia cases only.
The sensitivity of ODK0501 was significantly higher (P = 0.002) and the specificity was >95% when compared with Binax NOW. The negative predictive value of Binax NOW was also lower than that of ODK0501. These data indicated ODK0501 is superior to Binax NOW. However, because S. pneumoniae can be indigenous to the nasal cavity, nasopharyngeal and intraoral regions of some of the elderly, infants and children (1, 9) sputum or nasopharyngeal samples obtained from such individuals might be S. pneumoniae-positive with ODK0501. The question will be raised that the higher sensitivity of ODK0501 suggests that indigenous, colonizing S. pneumoniae in the respiratory tract detected by this method will be considered as the cause of infection and lead to over diagnosis. To answer this question, we measured amounts of S. pneumoniae in expectorated sputum. Psp A has being originally considered as a potential antigen and 21 virulence factor of S. pneumoniae (15) NOW-negative arm. We found that only underlying COPD statistically differed among all tested factors, though the number of COPD cases was only thirteen. In these COPD patients, age, prior antibiotics use, WBC count, CRP level, copy numbers of Psp A gene and days from onset until assay were compared and no significant differences between Binax-positive and -negative populations were found (data not shown). Although whether the detection rate of Binax NOW decreases in COPD patients remains unknown, ODK0501 was more sensitive in the present study.
The relationships between the severity of pneumonia and the sensitivity of ODK0501
and Binax NOW are also important. We compared the performance of ODK0501 and Binax NOW with the severity of pneumonia scored according to the definitions in the "The Japanese Respiratory Society Guidelines for the Management of Community-Acquired Pneumonia in Adults" among patients with community-acquired pneumonia and found no significant differences between the detection rates of pneumococcal pneumonia at any level of severity between the two assays (data not shown).
In conclusion, since ODK0501 evaluates sputum sampled from local sites of infection, the results reflect the real-time status of infection due to S. pneumoniae. Our study indicated ODK0501 was statistically more sensitive than the Binax NOW Streptococcus 24 pneumoniae urinary antigen test, suggesting that ODK0501will significantly contribute to the early, rapid and non-invasive diagnosis of pneumococcal infection in adult. Copy numbers significantly differed between ODK0501-positive and -negative populations (P < 0.001).
